Tumor microvasculature with endothelial fenestrations inVHLnull clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy

JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma

(2011) T Kanno et al.   ONCOGENE

Genetic and Functional Studies Implicate HIF1  as a 14q Kidney Cancer Suppressor Gene

(2011) C. Shen et al.   Cancer Discovery

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

(2010) Keith T. Flaherty et al.   CANCER BIOLOGY & THERAPY

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

(2010) Adrian M Jubb et al.   LANCET ONCOLOGY

Chemokine (C-C Motif) Ligand 2 Engages CCR2+Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone

(2009) Xin Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma

(2009) Henk M.W. Verheul et al.   UROLOGY

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

(2008) John D. Gordan et al.   CANCER CELL

von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma

(2008) Toni K. Choueiri et al.   JOURNAL OF UROLOGY